E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
ST elevated Myocardial infarction (STEMI) |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Cardiovascular Diseases [C14] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10064346 |
E.1.2 | Term | STEMI |
E.1.2 | System Organ Class | 100000004849 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess the efficacy of crushed vs. integral tablets of prasugrel loading dose treatment by comparing the percentage of patients reaching the co-primary endpoint of TIMI flow grade 3 of MI culprit vessel at initial angiography or a ≥70% ST-segment elevation resolution 60min post-PCI. |
|
E.2.2 | Secondary objectives of the trial |
- level of platelet inhibition at first medical contact, beginning and end of PCI procedure, as well as at 4 hours after prasugrel administration - platelet reactivity, at each time point as well as over time - rates of HPR - exploratory analyses within each group to evaluate any differences in PD among patients receiving morphine - Time –relationship (from symptom onset to 1st dose intake) on each primary - Time –relationship (from 1st dose intake to/ angiography and to ECG 1h after PCI) on each primary - ≥70% ST-segment resolution pre-PCI and directly after PCI - Corrected TIMI frame count (cTFC) at angiography, pre and post PCI - TIMI myocardial perfusion grade (TMPG) at angiography, pre and post PCI - TIMI myocardial blush grade at angiography, pre and post PCI - TIMI flow grade 3 at end of procedure - Composite of death, MI, stroke, urgent revascularization and acute stent thrombosis in-hospital, during 30 days and 12 months of treatment
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Consecutive patients with STEMI planned for primary PCI:
- Deferred written informed consent within 4 hours after prasugrel loading dose - Adult men and women aged at least 18 years - Symptoms of acute MI of more than 30 min but less than 6 hours - New persistent ST-segment elevation ≥ 1 mm in two or more contiguous ECG leads
|
|
E.4 | Principal exclusion criteria |
- Contraindication to prasugrel (e.g., hypersensitivity, active bleeding, history of previous intracranial bleed, history of any CVA including TIA, moderate to severe hepatic impairment, GI bleed within the past 6 months, major surgery within past 4 weeks) - Patient who has received loading dose of clopidogrel or ticagrelor for the index event or are on chronic treatment of ticagrelor, or prasugrel. Patients on maintenance dose clopidogrel for at least 7 days are included. - Oral anticoagulation therapy that cannot be stopped (i.e. patients requiring chronic therapy) - Planned fibrinolytic treatment - Patient requiring dialysis - Known, clinically important thrombocytopenia - Known clinically important anaemia - Known pregnancy or lactation - Need for a concomitant systemic therapy with strong inhibitors or strong inducers of CYP3A - Condition which may either put the patient at risk or influence the result of the study (e.g., cardiogenic shock with severe hemodynamic instability, active cancer, risk for non-compliance, risk for being lost to follow up) - Patient unable to swallow oral medication (i.e. intubated patients)
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Co-primary endpoint is the percentage of patients reaching TIMI flow grade 3 of MI culprit vessel at initial angiography or a ≥70% ST-segment resolution 60min post-PCI |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
Percentage of patients in the following: composite of death, MI, stroke, urgent revascularization and acute stent thrombosis during inhospital stay, 30 days and 12 months of study Percentage of patients in the following: composite of death, MI, or urgent revascularization during inhospital, 30 days and 12 months of study Percentage of patients presenting with any of the individual endpoints during inhospital, 30 days and 12 months of study Percentage of patients receiving thrombotic bail-out with GPIIb/IIIa inhibitors at initial PCI Complete (≥ 70%) ST-segment elevation resolution pre -PCI and directly post-PCI Corrected TIMI frame count (cTFC) at angiography, pre and post PCI TIMI myocardial perfusion grade (TMPG) at angiography, pre and post PCI Time from symptom onset to 1st dose intake correlated to TIMI flow grade 3 of MI culprit vessel at initial angiography and on ≥70% ST-segment elevation resolution 60min post-PCI Time from first dose intake to ECG correlated to ≥70% ST-segment elevation resolution 60min post-PCI and time from randomization to initial angiography correlated to TIMI flow grade 3 of MI culprit vessel TIMI flow grade 3 at end of procedure Myocardial blush at the start and end of the procedure Maximum CK, and CK-MB levels PRU measurements at first medical contact, beginning and end of PCI, as well as 4 after drug administration PRU measurements at first medical contact, beginning and end of PCI, as well as 4hours after drug administration Percentage of patients with PRU values over HPR threshold PRU of each group among patients stratified for morphine treatment Percentage of patients having a bleeding event defined by the TRITON TIMI-38 and BARC bleeding definitions, within the first 48 hours, (i.e. primary safety endpoint) during 30 days and 12 months of study Interaction analysis on primary and secondary endpoints depending on stratified randomization group (clopidogrel naïve vs. clopidogrel MD) A secondary efficacy analysis will be performed in: a) all randomized patients b) all STEMI patients who underwent primary PCI
|
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | No |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | Yes |
E.8.2.3.1 | Comparator description |
comperator will Efient as integral tablets,study medication will be Efient as crushed tablets. |
|
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | |
E.8.9.1 | In the Member State concerned months | 42 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial months | 42 |